A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatment

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2K citations · Full text

Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for <i>F508del-CFTR</i>

Carlos Milla, Félix Ratjen, Gautham Marigowda et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 164 citations · Full text

The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors

Werner J. Pichler · World Allergy Organization Journal · 2008 · 88 citations · Full text

Serum sickness‐like reaction following initiation of elexacaftor/tezacaftor/ivacaftor therapy

Steven K. Brennan, Itay Marmor, Christine N. Schafer et al. · Pediatric Pulmonology · 2020 · 12 citations

Serum Sickness‐like Reaction, Therapeutic Efficacy, Experimental Therapeutic +3

‘Triple therapy’ (elexacaftor, tezacaftor, ivacaftor) skin rash in patients with cystic fibrosis

May Khei Hu, Genna Wood, Owen Dempsey · Postgraduate Medical Journal · 2020 · 12 citations

Molecular Diagnostic Techniques, Inflammatory Lung Disease, Advanced Lung Disease +15